


"The right tools for real impact - why quality matters"

TAFS Workshop: "Right Tools, Real Impact: Evaluation and Use of FMD Vaccines and Diagnostics in the Field"

Nadav Galon former CVO and FAO/WOAH expert



November 2025, Bangkok



Ancient Greek philosopher

"PANTA REI" everything flows

"You could not step twice into the same river"


HPAI ASF LSD BT FMD



WOAH global map - "Grey zones" Sept-2025

WOAH Members' official FMD status map


Last update September 2025






TAFS Bangkok 2025

FMD epidemiological significant outbreaks July 2025




FMD in Eurpoe






Asia and Pacific June-2025



FMD pools

WOAH Members' official FMD status map


Last update April 2024






TAFS Bangkok 2025

"Change is the only constant" Evolution or Revolution




Charles Darwin



Karl Marks





FMD SAT1: Situation Update & Recommendations for Prevention and Response in the Near East and beyond



Food and Agriculture Organization of the United Nations

220K subscribers






FMD strains ("inter-pool") mobilty

 Escapes of FMDV lineages endemic in East Africa have been historically recorded for serotypes A, O, SAT1 and SAT2 viruses, with documented examples including:

0	O/EA-2 [2019]	O/EA-3 [1974]	
Α	A/G-I	A/G-II	A/G-VII
	[2018]	[1985]	[1989]
SAT1	SAT1/?	SAT1/I	SAT1/VI
	[1970]	[2023]	[1962]
SAT2	SAT2/IV [1990]	SAT2/VII [2012]	





FAO update May 2025




Inter-regional animal trade "formal and non-formal"

Cattle movements out of Africa 2008-2013

Live bovine movements 2008-2013 (Average_Qt)

Cattle movements in Turkey




Pink- Countries reporting LSD in 2011-2014 according to OIE

EFSA Journal 2015; 13(1):3986



FMD - Mediterranean 2022- 23




Source: FMD outbreaks in the Middle East and North Africa between Mar 2022 - Feb 2023

Department for Environment, Food and Rural Affairs (DEFRA UK)



Iraq FMD SAT-1 in 2025



FMD SAT1: Situation Update & Recommendations for Prevention and Response in the Near East and beyond FAO 2025



Azerbaijan reporting SAT-1 FMD 10-2025



WAHIS

Black Sea Georgia Azerbaijan Ankara⊚ Türkiye Turkme **⊚**Tehran Syria Lebanon Iraq rael Iran _{iro}∖Jordan Kuwait Persian Gulf

Azerbaijan - Foot and mouth disease virus (Inf. with) - Immediate notification

GENERAL INFORMATION

ZONE

COUNTRY/TERRITORY OR ZONE

DISEASE

Foot and mouth disease virus (Inf. with)

ANIMAL TYPE

TERRESTRIAL

CAUSAL AGENT

Foot and mouth disease virus

DISEASE CATEGORY

Listed disease

GENOTYPE / SEROTYPE / SUBTYPE

SAT1

START DATE

EVENT ID

6951

2025/10/25

https://wahis.woah.org/#/in-review/6951



TAFS Bangkok 2025

SAT 1 strain



SAT1 strains have shown limited circulation in recent decades

- Many manufacturers have discontinued production of SAT1 vaccines
- The SAT1 strains available for vaccine production are outdated and matching data are missing

Sharing of the actual SAT1 strains

- Biosafety/biosecurity issues (live virus to be shared)
- FAO/WOAH/WRL Ref centres/labs to be involved
- Must be coordinated on the international level

FMD SAT1: Situation Update & Recommendations for Prevention and Response in the Near East and beyond FAO 2025



Production of FMD vaccine from an isolate

- Adaptation to cell culture
- Strain characterization
 - Biological
 - Antigenic
 - Molecular
- Vaccine production and quality control
- Vaccine registration/licensing in the country of origin

FAO: Situation Update & Recommendations for Prevention and Response in the Near East and beyond 2025



FMD vaccines production

- National / Regional / Global
- Public / Private / PPP
- Autogenic
- Capability
- Investments
- Updating
- Dosier
- Transparency







National FMD vaccine production

- Expensive and ever-growing demands
 - R&D
 - Production facilities
 - Quality Assurance (GMP)
 - Documentation and record keeping
 - Production process
 - Process validation
 - Stability tests
 - Tests to demonstrate safety and efficacy
 - Safe for user, environment

- Difficult in small scale
- Country or Business
- Fewer players
- Global players



BSL-3 facility KVI VS Israel















Technical Item

VETERINARY VACCINES AND VACCINATION: from science to action – reflections for change

Authors: Baptiste Dungu¹, Meritxell Donadeu²

¹ Bonisa Solutions Itd.; Initiative for Neglected Animal Diseases (INAND)

² Independent consultant; Initiative for Neglected Animal Diseases (INAND)

With support from: Gregorio Torres³, Javier Yugueros-Marcos³, Andrés García-Campos³, Rachel Tidman³, Charmaine Chng³, Mariana Delgado³, Francisco D'Alessio³ and Ramanan Laxminarayan⁴

³ World Organisation for Animal Health (WOAH); ⁴ One Health Trust











VACCINE ADOPTION

Vaccine availability



Vaccine access



Vaccine demand

Farm level



Effective and safe vaccines
exist, are produced at a
large scale and are
purchasable on the market;
it refers to the product itself.

Farmers can access vaccines from sellers or manufacturers because they are locally available, and vaccines are affordable. Farmers are aware of the existence of a vaccine and want to use it because they value the potential benefits of using the vaccine.

National level



Vaccines conforming to national and international quality standards and fit for purpose (for example DIVA* if applicable), exist.

DIVA: Differentiate infected from vaccinated animals

Vaccines are registered or authorised for use by the national Veterinary Services and can be procured. Vaccination strategies are designed and implemented as per national and international standards, vaccinovigilance is in place, and vaccination is accepted and desired by the population



TAFS Bangkok 2025

WOAH on vaccine production

Potential WOAH contribution:

 WOAH to encourage Members to reassess and evaluate vaccine supply structures and governance.

Potential Member contributions:

 Members without adequate facilities or expertise to produce all necessary veterinary vaccines with the quality recommended by international standards to consider different technical and commercial options before engaging in national manufacturing.

Potential Pharmaceutical company contributions:

 Local vaccine producers that are faced with challenges to produce the right vaccines in enough quantity or quality to develop collaborations with other companies including PPP approaches.





FMD vaccine producers - 29 facilities

Company	Location of production sites
Biogénesis Bagó	Argentina/ Brazil
Biovet Private Ltd	India
Boehringer-Ingelheim (BI)	France/UK/ Brazil
Botswana Vaccine Institute (BVI)	Botswana
Brilliant Bio Pharma	India

BWAT Bio. Science and Technology (website says Inner Mongolia Bigvet Biotech Co., Ltd.)	China
China Agricultural Vet. Bio. Science and Technology	China
Department of Livestock Development (DLD)	Thailand
Dollvet	Türkiye

TAFS forum

TAFS Bangkok 2025



FMD vaccine – Formulation plants

Company	Location of production sites	Antigen source		
Biopharma	Morocco			
FVC Co. Ltd	South Korea	Biogenesis Bago		
Dong Bang	South Korea	FGBI-ARRIAH		
Navetco	Vietnam			
Vetvaco	Vietnam	BI		

The European Commission for the Control of Foot-and-Mouth Disease (EuFMD)







Who we are

Global situation

What we do

Progressive Learning Pathway

Meetings and Events

Tools

Resources

Public Summary Report (PSR

PQv list

Committee for Prequalification (SCPQv

Vaccine Prequalification

BIOAFTOGEN

AFTOPOR

DECIVAC FMD DOE


AFTOVAXPUR

Source: WRLFMD



TAFS Bangkok 2025

FMD diagnosis



FMD outbreaks



Diagnosis and sampling capacity



Expertise
Training
Experience
Resources





Sampling training and research



Home Our science V Engage with us V Facilities and resources V Careers and learning V News V About V



Scientists from The Pirbright Institute have led a longitudinal study of foot-and-mouth disease (FMD) in collaboration with the National Veterinary Research Institute (NVRI) in Northern Nigeria.

www.pirbright.ac.uk/news/field-study-sampling-foot-and-mouth-disease



FMD lesion sampling

- Incubation period is highly variable
- Depends on strain, dose, route, species
- Physiology, immunology, husbandry conditions

- Field- typically 2 to 5 days
- WOAH -Terrestrial Code -14 days incubation







image source: EU FMD

Testing site – field or lab

- WOAH certified kit 2023
- VDRG® FMDV 3Diff/PAN Ag Rapid kit
- Pen-side test
- Serotypes A, O and Asia-1
- Cattle or pig samples
- Tissue /fluid samples

MEDIAN Diagnostics Inc.

VDRG® FMDV 3Diff/PAN Ag Rapid kit


Cat. No. PM-FMD-16

For in-vitro veterinary diagnostic use only



Validated and certified by WOAH as fit for the purposes defined in this instruction manual.

Registration number: WOAH 022029



Both control and test lines are red



FMD sampling and reporting




Figure 1: Samples tested by WRLFMD or reported in this quarter. ● indicates samples analysed; × indicates outbreaks reported/updated to the WOAH this quarter; □ indicates reports of FMD from other sources. Shape colours define the serotype detected ●O; ●A; ●C; ●Asia1, ●SAT1, ●SAT2, ●SAT3, ● serotype undetermined/not


Source: WRLFMD. Map conforms to the United Nations World map, June 2020




Traceability and Sero-surveillance

Samples collected from suspected herds

- Nasopharynx
- Serology






Source: Israel Vet Services



NSP sero-surveillance — RM farm 2011 IL




NSP-free vaccine is crucial for NSP- sero-surveillance



TAFS Bangkok 2025

Testing vaccine strain efficacy



Optimal combination

VNT ≥ 1.42

and

 $r1 \ge 0.3$

- 5 calves
- Vaccinated ≥ once
- 21-30 after last vaccination

Matching vaccine field strains results


	O3039	BI O- PanAsia0 2	O- Manisa	MSD O- TUR/5/0 9	BB O1- Campos (biogene sis)	BI O1- Campos (Boehrin ger)	
Isolate: O/JOR/10/2021	0.37 (1.53)	0.23 (1.84)	0.11 (1.61)	0.35 (1.92)	0.18 (2.09)	0.22 (1.85)	r 1 vnt
Isolate: O/JOR/6/2021	0.36 (1.54)	0.30 (1.95)	0.19 (1.82)	0.56 (2.12)	0.25 (2.24)	0.17 (1.73)	r1 vnt

Vaccines originating from other pools may protect



TAFS Bangkok 2025

Duration of immunity





"Vaccines don't protect, vaccination does"

The Lancet Regional Health - Western Pacific 6 (2021) 100099



Contents lists available at ScienceDirect

The Lancet Regional Health - Western Pacific



journal homepage: www.elsevier.com/locate/lanwpc


Editorial

Vaccines don't save lives, vaccination does

www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(21)00008-0/fulltext





More livestock - more investments - better protection





FMD AMR One-Health







Summary

- Valuable animals quality vaccines
- Cost-Benefit
- Efficacy & effectiveness
- NSP free vaccines
- Traceability & surveillance
- Vaccines and vaccination










Human era - Paradigm shift





"Very Few Things are Simple Black and White"



Thank You
Nadav.galon@gmail.com

